Muhammad Tayyeb

Muhammad Tayyeb

Auto-generated profile, based on publicly available information

Muhammad Tayyeb

Internal Medicine, Monmouth Medical Center, LONG BRANCH, NJ, United States

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 March 2023 in Journal of Religion and Health
Verified
Journal Article
Closed access
PDF file
METİN YILDIZMETİN YILDIZ
METİN YILDIZ
EFEzomo Ojeiru Felix
Ezomo Ojeiru Felix
OAOlugbenga Ademiju
Olugbenga Ademiju
TNTajudeen Oluwafemi Noibi
Tajudeen Oluwafemi Noibi
RGRoseline Florence Gomes
Roseline Florence Gomes
AŞAylin Şengan
Aylin Şengan

29 July 2021 in Turkish Journal of Internal Medicine
Verified
Journal Article
Open access
PDF file
METİN YILDIZMETİN YILDIZ
METİN YILDIZ
MYMehmet Salih Yildirim
Mehmet Salih Yildirim
ATAbraham Tani̇mowo
Abraham Tani̇mowo
RKRam Bahadur Khadka
Ram Bahadur Khadka
AGApurba Gohai̇n
Apurba Gohai̇n
GOGüray Okyar
Güray Okyar
Objectives: This research was conducted to determining the health literacy levels and attitudes of ındividuals in different countries towards vaccination Material and Methods: This study is cross-sectional, comprised of eight hundred and and thirty eight participants (n=838) drawn from communities in eight different countries; Turkey (Agri), Nigeria (Ibadan), Pakistan (Charsadda), India (Assam), Malaysia (Ipoh), Madagascar (Antananarivo), Indonesia (Bandung), and Nepal (Kathmandu) between September-October 2020. Results: The Health Literacy scale total score mean was 54.92±23.64. Vaccine Reliability Scale Total Score Means 55.38±12.99. It was found that there was a statistically significant negative correlation between Health Literacy scale total score mean and Vaccine Reliability Scale Total Score Means and two Vaccine Reliability Scale sub dimension; Vaccine Benefit Perception and Trust in Healthcare Professionals. Conclusions: The Health Literacy total score mean was found to be statistically significantly higher among Nepal nationality, male, civil servant and those who do not think the COVID-19 vaccine will be effective and those who do not think they will receive the COVID vaccine if it is free (p

9 October 2023 in Women's Studies International Forum
Verified
Journal Article
Closed access
METİN YILDIZMETİN YILDIZ
METİN YILDIZ
RGRoseline Florence Gomes
Roseline Florence Gomes
EFEzomo Ojeiru Felix
Ezomo Ojeiru Felix
OAOlugbenga Ademiju
Olugbenga Ademiju
MTMuhammad Tayyeb
Muhammad Tayyeb
SMSara Muçaj
Sara Muçaj

23 August 2021 in Aegean Journal of Obstetrics and Gynecology
Verified
Journal Article
Open access
PDF file
METİN YILDIZMETİN YILDIZ
METİN YILDIZ
ATAbraham Tanimowo
Abraham Tanimowo
MTMuhammad Tayyeb
Muhammad Tayyeb
MYMehmet Salih Yildirim
Mehmet Salih Yildirim
YSYakup Sarpdağı
Yakup Sarpdağı
GOGüray Okyar
Güray Okyar
Objective: To determine the homophobia level of ındividuals in different countries. Material and methods: A descriptive cross-sectional study among 518 individuals of ages 18 years and above living in Turkey (Agri), Nigeria (Ibadan), Pakistan (Charsadda), India (Punjab), Bangladesh (Chittagong) and Nepal (Kathmandu). Using google form they completed a demographic characteristics form and Hudson and Ricketts Homophobia Scale Results: The homophobia scale total score mean was 92.97 ± 27.47. The total score means the homophobia scale was statistically significantly higher among Nigeria nationality, religious belief Christian, male, health personnel and those who do not have a homosexual acquaintance (p <0.05). A statistically significant relationship was also found between homophobia scale total score mean and age (p <0.05). Conclusion: Nationality, religion, gender, occupation, age and whether or not one has homosexual acquaintances are key demographic correlates of homophobia level. However, the study recommends that further investigation should be conducted with a larger group for a proper inference of causation to be drawn.

5 November 2020 in Blood
Verified
Journal Article
Open access
MSMuhammad Khawar Sana
Muhammad Khawar Sana
SASyed Maaz Abdullah
Syed Maaz Abdullah
MTMuhammad Tayyeb
Muhammad Tayyeb
MDMohammad Ammad Ud Din
Mohammad Ammad Ud Din
AEAmrat Ehsan
Amrat Ehsan
FAFaiz Anwwer
Faiz Anwwer
Introduction: Primary CNS lymphoma (PCNSL) is a highly aggressive non-Hodgkin lymphoma (NHL) variant limited to the CNS with rare evidence of systemic spread. It constitutes 4% of all CNS malignancies. Owing to the impenetrable blood-brain barrier to routine chemo-immunotherapy, the efficacy of such treatment is less than optimal. The combination of chemoradiotherapy has substantial associated risk of late neurotoxicity and increased disease recurrence. High dose chemotherapy (HDT) with autologous stem cell transplantation (ASCT) as rescue has been shown to be effective. We performed a systematic review of literature to explore the efficacy of HDT and ASCT in patients with PCNSL. Methods: We performed a comprehensive literature search (following PRISMA guidelines) on May 28, 2020 on Pubmed, Cochrane Library and Clinicaltrials.Gov by using the MeSH terms related to high-dose chemotherapy, autologous transplantation and primary CNS lymphoma which yielded 561 relevant articles. Following subsequent screening by 2 reviewers, we selected 16 published trials (n=745) and included data from these studies in our systematic review. We manually extracted data summarized the results. Results: 405/745 patients eventually underwent sequential HDT+ASCT the results of which are illustrated in table 1 and 2 stratified on the basis of newly diagnosed (ND) (n=641) and relapsed, refractory (RR) PCNSL patients (n=104) respectively. ND PCNSL: Among ND PCNSL patients, carmustine and thiotepa based regimens were the most widely studied HDT regimens (n= 351). Illerhaus et al. (2016, n= 81) in a phase 2 trial used HDT of intravenous (IV) combinations of rituximab, thiotepa and carmustine followed by ASCT on 73 patients which yielded partial response (PR) 13.9 %, complete response (CR) 77.2% and overall survival (OS) 81% at 36 months. 4 patients suffered transplant related mortality (TRM), mucositis (8%) and arrhythmias (2%) were the most common nonhematologic >grade 4 adverse effects. Ferreri et al. (2017) [n=122] in a phase 2 trial (n=59) used ASCT following Carmustine + Thiotepa HDT and reported 2-year OS of 71% and CR of 93% with a modest toxicity profile (infections (8%), mucositis (5%) and 2 (3%) treatment related deaths). IV thiotepa, busulfan and cyclophosphamide (TBC) combination was used as HDT / ASCT in ND PCNSL patients (n=208). Omuro et al. (2015) (n=32) used HDT with TBC followed by ASCT in 26 patients. Whole brain radiation therapy (WBRT) was not given to any patient regardless of recurrence or relapse. At 5 years, the study reported PR=11%, CR=81%, and OS=81%. In a phase 2 trial, Houillier et al. (2019, n=140) used TBC combination as HDT followed by either WBRT or ASCT (2 separate arms), 44 patients of the latter arm exhibited a CR of 38% and OS of 66% at 5 years with 5 treatment related deaths. An IV combinations of carmustine, etoposide, cytarabine and melphalan (BEAM) have also been used as HDT with ASCT in 3 phase 2 trials (n=59). Abrey et al. (2003, n=28) in a phase 2 trial used high-dose BEAM therapy followed by ASCT which yielded PR of 14%, CR of 57% and OS of 55% at 28 months. Only 1 treatment related mortality occurred. RR PCNSL: TBC combination has been the most extensively used HDT regimen for RR PCNSL patients undergoing ASCT (n=65). Soussain et al. (2008, n=43) conducted a phase 2 trial in which high-dose TBC sequentially followed by ASCT was studied in 27 RR PCNSL patients. The results showed median PFS of 41.1 months with OS of 45% at 2 years however, 3 toxicity related deaths were observed. Kasenda et al. (2017, n=39) in a phase 2 trial used high-dose combination of rituximab, carmustine and thiotepa coupled with ASCT on RR PCNSL patients which yielded PR of 15.4%, CR of 56% and median PFS of 12.4 months with an OS of 56.4% at 2 years. However, there were 4 treatment related deaths and an extensive toxicity spectrum with widespread pancytopenia (thrombocytopenia =96.9%, leukopenia =100%, anemia =65.6%) and nonhematologic infections (65.6%) observed. Conclusion: HDT followed by ASCT rescue has exhibited favorable outcomes and can be used an alternative to WBRT especially in ND PCNSL patients. Evidence is limited by mainly phase II non randomized data. Although, hematologic adverse effects due to HDT were observed on a widespread basis, transplant related mortality was however minimal. There is need to carry out prospective randomized phase III trials to access the safety and efficacy profile of HDT / ASCT for ND and RR PCNSL. Table Disclosures: Anwer: Incyte, Seattle Genetics, Acetylon Pharmaceuticals, AbbVie Pharma, Astellas Pharma, Celegene, Millennium Pharmaceuticals.: Honoraria, Research Funding, Speakers Bureau.

1 May 2023
Verified
Conference Paper
Closed access
PBP. Bhide
P. Bhide
GMG. Mohan
G. Mohan
MTM. Tayyeb
M. Tayyeb
CVC.H. Vyas
C.H. Vyas
PAP.V. Angi
P.V. Angi